Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, January 03, 2018
Orbis Biosciences has entered into an exclusive global license agreement leveraging its Precision Particle Fabrication technology.
read more
Evergreen Discovery (Evergreen), a radiopharmaceutical drug development company with a focus on the treatment and diagnosis of cancer, and Orbit Discovery Ltd (Orbit), a provider of discovery services for therapeutic peptides, have entered into a ...
read more
Orbit Discovery Limited announced it has entered into a Master Service Agreement with SanegeneBio Inc. The focus of the collaboration is to identify tissue-specific delivery of a wide range of RNA therapeutics to efficiently knock down disease-...
read more
Orbit Discovery has announced the commencement of a partnership with WuXi AppTec, a global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry.
read more
Orbita has secured $9 million of venture funding as part of the company's Series A financing round.
read more
Orchard Therapeutics, a clinical-stage biotechnology company dedicated to bringing transformative ex-vivo gene therapies to patients with serious and life-threatening orphan diseases has announced an alliance with PharmaCell B.V., a Contract ...
read more
Orchard Therapeutics has entered a new clinical manufacturing services agreement with PCT Cell Therapy Services.
read more
Orchard Therapeutics and MolMed have extended their collaboration – initiated in April 2018 – for a period of five years through June 2025.
read more
Oregon Freeze Dry Life Sciences announced multiple leadership appointments to its recently created Life Sciences division and the appointment of CDMO veteran Jim Miller to its board of directors.
read more
The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Actavis. In its application, Actavis seeks to market and sell generic versions of the currently approved doses of Contrave®.
read more
Monday, November 13, 2017
Orexigen Therapeutics announced its wholly owned subsidiary and Merck KGaA, Darmstadt, Germany have executed a distributorship agreement for Contrave.
read more
Wednesday, August 21, 2019
Orexo has entered into an exclusive agreement with GAIA AG for a new digital therapy (DTx) for the treatment of Opioid Use Disorder (OUD). Orexo will have the exclusive global commercial rights to the product and intends to launch it in the US in ...
read more
OrganaBio has acquired substantially all of the operating assets of San Diego-based Excellos Inc. to create a bicoastal cell therapy contract development and manufacturing organization.
read more
OrganaBio announced the opening of a new laboratory facility in Irvine, California, further expanding its reach and capabilities from the southeast to the west coast.
read more
Orgenesis it has entered into a Collaboration Agreement with Educell, a European cell therapy company.
read more